AFP in hepatocellular carcinoma

1 EU-approved indication in hepatocellular carcinoma needs a AFP result: ramucirumab (2nd line, advanced).

Line of therapy

Approved indications, Hepatocellular carcinoma
DrugBiomarker requirementRegimenSettingConditions
AFP1
Serum AFP ≥ 400 ng/ml
Monotherapy
2L
advanced
After sorafenib

10 approvals for HCC need no biomarker and apply whatever the result. All approvals for HCC

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Ramucirumab (Cyramza)
    Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.